Intracoronary macrothrombus formation during percutaneous coronary intervention despite optimal activated clotting time using bivalirudin: A case report

Angiology

Volumn 56, Issue 6, 2005, Pages 761-765

  Tadros, George M ^a,b   Broder, Kevin ^a,c   Bachour, Fouad ^a,d  

^a University of Minnesota ^*

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ARGATROBAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRUDIN; HIRULOG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; NITRIC ACID DERIVATIVE; THROMBIN INHIBITOR;

ADULT; ANGIOGRAPHY; ANGIOPLASTY; ARTICLE; BLOOD CLOTTING TIME; CASE REPORT; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; CORONARY STENT; DIABETES MELLITUS; FEMALE; HEART INFARCTION; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; THROMBOGENESIS;

EID: 29044440734     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331970505600614     Document Type: Article

References (20)

1. Boston DR, Malouf A, Barry WH: Management of intracoronary thrombosis complicating percutaneous transluminal coronary angioplasty. Clin Cardiol 19:536-542, 1996.
2. Lincoff M; Bittl J; Harrington R, et al: Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289:853-863, 2003.
3. Kong TQ, Davidson CJ, Meyers SN, et al: Prognostic implications of creatine kinase elevation following elective coronary interventions. JAMA 227:461-466, 1997.
4. Abdelmeguid AE, Topol EJ, Whitlow PL, et al: Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation 94:1528-1536, 1996.
5. Klein LW, Kramer BL, Howard E, et al: Incidence and clinical significance of transient creatine kinase elevations and the diagnosis of non-Q wave myocardial infarction associated with coronary angioplasty. J Am Coll Cardiol 17:621-626, 1991.
6. Ohman EM, Tardiff BE: Periprocedural cardiac marker elevation after percutaneous coronary artery revascularization. JAMA 227:495-497, 1997.
7. Tardiff BE, Califf RM, Tcheng JE, et al: Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. J Am Coll Cardiol 33:88-96, 1999.
8. Kini A, Kini S, Marmur JD, et al: Incidence and mechanism of creatine kinase-MB enzyme elevation after coronary intervention with different devices. Cathet Cardiovasc Interv 48:1213-1219, 1999.
9. Mehran R, Dangas G, Mintz GS, et al: Atherosclerotic plaque burden and CKMB enzyme elevation after coronary interventions. Circulation 101:604-610, 2000.
10. Saucedo F, Mehran R, Dangas G, et al: Long-term clinical events following creatine kinase myocardial band isoenzyme elevation after successful coronary stenting. J Am Coll Cardiol 35:1134-1141, 2000.
11. Grayburn PA, Willard JE, Brickner ME, et al: In vivo thrombus formation on a guidewire during intravascular ultrasound imaging: Evidence for inadequate heparinization. Cathet Cardiovasc Diagn 23:141-143, 1991.
12. Moreyra AE, Khaw K, Wilson AC, et al: Effect of prolonged blood contact time on deposition of cellular and amorphous material on teflon-coated guidewires: A scanning electron microscopy study. Cathet Cardiovasc Diagn 38:355-359, 1996.
13. Ragosta M, Karve M, Brezynski D, et al: Effectiveness of heparin in preventing thrombin generation and thrombin activity in patients undergoing coronary intervention. Am Heart J 137:250-257, 1999.
14. Popma JJ, Weitz J, Bittl JA, et al: Antithrombotic therapy in patients undergoing coronary angioplasty. Chest 114:7285-7415, 1998.
15. Narins CR, Hillegass WB Jr, Nelson CL, et al: Relation between activated clotting time during angioplasty and abrupt closure. Circulation 93:667-671, 1996.
16. Ferguson JJ, Barasch E, Wilson JM, et al: The relation of clinical outcome to dissection and thrombus formation during coronary angioplasty: Heparin Registry Investigators. J Invasive Cardiol 7:2-10, 1995.
17. McGarry TF Jr, Gottlieb RS, Morganroth J, et al: The relationship of anticoagulation level and complications after successful percutaneous transluminal coronary angioplasty. Am Heart J 123:1445-1451, 1992.
18. Chew D, Bhatt D, Lincoff M, et al: Defining the optimal activated clotting time during percutaneous coronary intervention aggregate results from 6 randomized, controlled trials. Circulation 103:961-966, 2001.
19. Blankenship J, Tasissa G, Conor O'Shea JC, et al: Effect of glycoprotein IIb/IIIa receptor inhibition on angiographic complications during percutaneous coronary intervention in the ESPRIT trial. J Am Coll Cardiol 38:653-658, 2001.
20. Islam MA, Blankenship J, Balog C, et al: Effect of abciximab on angiographic complications during percutaneous coronary stenting in the evaluation of platelet IIb/IIIa inhibition in stenting trial (EPISTENT). Am J Cardiol 90:916-921, 2002.